Active Equities to Watch in the Biotechnology Industry -- Prima Biomed, Oncothyreon, Opko Health, ImmunoCellular Therapeutics, and Adaptimmune Therapeutics

Jul 15, 2015, 09:00 ET from www.equityresearchinstitute.com

NEW YORK, July 15, 2015 /PRNewswire/ --

Equity Research Institute has initiated coverage on the following equities: Prima Biomed Ltd (NASDAQ: PBMD), Oncothyreon Inc. (NASDAQ: ONTY), Opko Health Inc. (NYSE: OPK), ImmunoCellular Therapeutics Ltd (AMEX: IMUC), and Adaptimmune Therapeutics PLC (NASDAQ: ADAP). Free research report on Prima Biomed can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=PBMD On Tuesday, July 14, 2015, the NASDAQ Composite ended at 5,104.89, up 0.66%, the Dow Jones Industrial Average advanced 0.42%, to finish the day at 18,053.58, and the S&P 500 closed at 2,108.95, up 0.45%. The gains were broad based as seven out of nine sectors ended the session in positive. Register for your complimentary reports at the links given below.  

Prima Biomed Ltd's stock surged 9.23%, to close the day at $1.42. The stock recorded a trading volume of 3.51 million shares, below its three months average volume of 4.45 million shares. Over the previous three months and since the start of this year, Prima Biomed Ltd's shares have rallied 129.03% and 111.94%, respectively. However, the stock has lost 27.55% in the last one month. The company's shares are trading 35.07% above their 200-day moving average. Additionally, Prima Biomed Ltd has a Relative Strength Index (RSI) of 50.26. Sign up and read the free notes on PBMD at:

https://www.EquityResearchInstitute.com/reports?keyword=PBMD

On Tuesday, shares in Oncothyreon Inc. recorded a trading volume of 1.30 million shares, lower than their three months average volume of 4.38 million shares. The stock ended the day 2.39% higher at $3.85. Although Oncothyreon Inc.'s stock has lost 0.77% in the last one month, it has surged 127.81% in the previous three months and 102.63% on YTD basis. The company is trading above its 50-day and 200-day moving averages by 20.30% and 83.82%, respectively. Furthermore, shares of Oncothyreon Inc. have an RSI of 61.99. The complimentary notes on ONTY can be downloaded in PDF format at:

https://www.EquityResearchInstitute.com/reports?keyword=ONTY

Opko Health Inc.'s stock gained 1.03%, to close Tuesday's session at $16.74. The stock recorded a trading volume of 3.54 million shares, below its three months average volume of 4.36 million shares. Over the last one month and the previous three months, Opko Health Inc.'s shares have advanced 7.45% and 13.49%, respectively. Additionally, the stock has surged 67.57% since the start of this year. The company is trading 3.44% and 34.57% above its 50-day and 200-day moving averages, respectively. Furthermore, Opko Health Inc.'s stock has an RSI of 57.56. Register for free on Equity Research Institute and access the latest research on OPK at:

https://www.EquityResearchInstitute.com/reports?keyword=OPK

ImmunoCellular Therapeutics Ltd's stock finished Tuesday's session 0.31% higher at $0.49. A total of 0.12 million shares were traded, which was below its three months average volume of 0.52 million shares. Over the last one month and the previous three months, ImmunoCellular Therapeutics Ltd's shares have advanced 1.89% and 3.15%, respectively. However, the stock has declined 33.56% on YTD basis. The company's shares are trading above their 50-day moving average by 0.79%. ImmunoCellular Therapeutics Ltd's stock has an RSI of 50.11. The complete research on IMUC is available for free at:

https://www.EquityResearchInstitute.com/reports?keyword=IMUC

On Tuesday, shares in Adaptimmune Therapeutics PLC ended the session 6.49% higher at $17.06. The stock reported a trading volume of 0.47 million shares, close to its three months average volume of 0.52 million shares. Adaptimmune Therapeutics PLC's shares have lost 11.56% in the last one month.  However, the stock has advanced 6.62% on YTD basis. The company is trading 0.27% below its 50-day and 200-day moving averages, each. Moreover, shares of Adaptimmune Therapeutics PLC have an RSI of 46.86. Free in-depth research on ADAP is available at:

https://www.EquityResearchInstitute.com/reports?keyword=ADAP

--

About Equity Research Institute: 

Equity Research Institute ("ERI") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ERI has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

ERI has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:  

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the CFA® have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the CFA® (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.

NO WARRANTY 

ERI, the Author, the Reviewer and the CFA® (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ERI nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.equityresearchinstitute.com.

RESTRICTIONS 

ERI is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia. Do not send email to robottrap (at) equityresearchinstitute.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE www.equityresearchinstitute.com